Basilea plans investments in R&D, with earnings from Cresemba and Zevtera sale

Basilea Pharmaceutica’s CEO David Veitch, will present at the 37th Annual J. P. Morgan Healthcare Conference on January 10, 2019, where he’ll describe both the progress made during 2018 and the priorities for 2019 to deliver on the key elements of Basilea’s strategy for continued value creation, the company said Friday.

Basilea is focused on continuously increasing revenues from its commercialized products, the antifungal Cresemba (isavuconazole) and the antibiotic Zevtera (ceftobiprole), in addition to advancing and expanding its oncology and anti-infectives R&D pipeline.

David Veitch said: “We have made a big step forward last year in the execution of our strategy. We are generating growing cash flows from our commercialized products Cresemba and Zevtera. This allows us to continue investing in our R&D pipeline, which is crucial for the future growth of our company. We remain focused on advancing our clinical oncology projects and our ceftobiprole phase 3 program to the next value inflection points, while looking at selectively strengthening our portfolio through both internal and external innovation.”

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.